BAY-293 (BAY293) is a novel, potent, cell-active small-molecule SOS1 inhibitor with anticancer activity. It acts by blocking the activation of RAS via disruption of the RAS-SOS1 interaction with an IC50 of 21 nM. BAY-293 was identified from a KRASG12C–SOS1cat NMR fragment-based screening assay and it can efficiently disrupt the interaction between KRAS and its exchange factor SOS1. Since the late 1980s, mutations in the RAS genes have been recognized as major oncogenes with a high occurrence rate in human cancers. Such mutations reduce the ability of the small GTPase RAS to hydrolyze GTP, keeping this molecular switch in a constitutively active GTP-bound form that drives, unchecked, oncogenic downstream signaling. One strategy to reduce the levels of active RAS is to target guanine nucleotide exchange factors, which allow RAS to cycle from the inactive GDP-bound state to the active GTP-bound form. The binding sites, mode of action, and selectivity were elucidated using crystal structures of KRASG12C-SOS1, SOS1, and SOS2. By preventing formation of the KRAS-SOS1 complex, these inhibitors block reloading of KRAS with GTP, leading to antiproliferative activity. The final compound 23 (BAY-293) selectively inhibits the KRAS-SOS1 interaction with an IC50 of 21 nM and is a valuable chemical probe for future investigations.

References: Proc Natl Acad Sci U S A. 2019 Feb 12;116(7):2551-2560.

Related CAS #: 2244904-70-7    2244904-14 (racemic)    2244904-69-4 (S-isomer)

These protocols are for reference only. InvivoChem does not independently validate these methods.